Source link : https://newshealth.biz/health-news/glp-1-microdosing-and-longevity-near-30-weight-loss-in-trial-2025s-top-research/
(MedPage Today) — As part of a longevity push, telehealth company Noom is now offering microdoses of GLP-1 receptor agonists outside the labels’ indications, including for people with a normal body mass index and no diabetes. In a phase III trial… Source link : https://www.medpagetoday.com/endocrinology/generalendocrinology/119048 Author : Publish date : 2025-12-16 19:06:00 Copyright for syndicated […]
The post GLP-1 Microdosing and Longevity; Near 30% Weight Loss in Trial; 2025’s Top Research first appeared on News Health.
—-
Author : News Health
Publish date : 2025-12-16 19:06:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8